Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
1. CHMP issued a negative opinion for Elevidys' authorization in DMD. 2. Sarepta paused Elevidys shipments due to FDA's additional data request. 3. Analysts express uncertainty about FDA's requirements for Elevidys resumption. 4. Sarepta faced setbacks in unrelated products and may miss payments to Arrowhead. 5. SRPT stock fell 7.53% to $11.91 amid ongoing market concerns.